Figure 3.
Neutralization of TNF⍺/LT⍺ by etanercept administration improves the antileukemic properties of anti-CD3. (A) Leukemia tumor burden (hCD45+/hCD7+) at the indicated time point (24 hours, 12 days) after treatment of leukemic mice with either 10 mg/kg etanercept, or 4 μg of OKT3 in presence or absence of 10 mg/kg etanercept. Experiments were performed using independent patient-derived xenografts (PDXs) derived from UPNT760 and UPNT663 diagnostic T-ALL cases, as indicated. Dark blue bar: control mice treated with control IgG2a and carrier solvent; light blue bar: etanercept-treated mice; red bar: anti-CD3–treated mice; orange bar: anti-CD3/etanercept cotreated mice. (B) Kaplan-Meier survival curves of NSG mice transplanted with T-ALL UPNT-760 and UPNT-663 as indicated and treated as in panel A. ∗P < 0.05; ∗∗P < 0.01.

Neutralization of TNF⍺/LT⍺ by etanercept administration improves the antileukemic properties of anti-CD3. (A) Leukemia tumor burden (hCD45+/hCD7+) at the indicated time point (24 hours, 12 days) after treatment of leukemic mice with either 10 mg/kg etanercept, or 4 μg of OKT3 in presence or absence of 10 mg/kg etanercept. Experiments were performed using independent patient-derived xenografts (PDXs) derived from UPNT760 and UPNT663 diagnostic T-ALL cases, as indicated. Dark blue bar: control mice treated with control IgG2a and carrier solvent; light blue bar: etanercept-treated mice; red bar: anti-CD3–treated mice; orange bar: anti-CD3/etanercept cotreated mice. (B) Kaplan-Meier survival curves of NSG mice transplanted with T-ALL UPNT-760 and UPNT-663 as indicated and treated as in panel A. ∗P < 0.05; ∗∗P < 0.01.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal